Interstitial Lung Disease

Co-Director
Interstitial Lung Disease Program
Selim M. Arcasoy, M.D.

Co-Director
Interstitial Lung Disease Program
David Lederer, M.D., M.S.

Co-Director
Interstitial Lung Disease Program
Nina Patel, M.D.

For Appointments
NewYork-Presbyterian/Columbia University Medical Center
622 West 168th Street
Vanderbilt Clinic VC 3-365
New York, NY 10032
P: (212) 305-8203
F: (212) 305-8426

For Referring Physicians
Physician Referral Form

NewYork-Presbyterian/Columbia University Medical Center offers a multidisciplinary program that optimizes the care of patients with many types of interstitial lung disease (ILD) including:

  • Idiopathic pulmonary fibrosis
  • Nonspecific interstitial pneumonitis
  • Hypersensitivity pneumonitis
  • ILD related to connective tissue diseases (such as lupus)
  • Pneumoconiosis
  • Drug-induced ILD

Our program features a team of specialists—including pulmonologists, thoracic surgeons, radiologists, a chest pathologist, pulmonary rehabilitation specialists, and a rheumatologist—who perform a detailed evaluation of each patient and tailor an individualized plan of care. That plan may include supportive therapy, medications, clinical research studies of new agents, and referral for lung transplantation when necessary.

The ILD team works closely with NewYork-Presbyterian Hospital’s renowned lung transplantation program for eligible patients in whom drug treatment has failed. Our team also evaluates patients for concurrent (and potentially treatable) pulmonary conditions (such as chronic obstructive pulmonary disease, sleep apnea, and deconditioning) to improve their overall lung health.

Forms

Download the ILD patient referral form.

Our Services

Lung biopsy showing normal lung tissue, with a healthy interstit

The ILD team at NewYork-Presbyterian/Columbia University Medical Center offers the following services for patients with interstitial lung disease:

  • Diagnostic evaluation using a number of approaches (including advanced imaging, bronchoscopy, and/or surgical lung biopsy, as appropriate) and multidisciplinary case review
  • Creation of a personalized treatment plan (which may include conventional or novel therapies)
  • Pulmonary rehabilitation
  • Management of coexisting pulmonary conditions (such as chronic obstructive pulmonary disease or obstructive sleep apnea)
  • Evaluation for and consideration of lung transplantation in eligible patients
  • Evaluation for and enrollment in novel research and investigational treatment studies for eligible patients

Clinical Trials

To learn more about clinical trials in interstitial lung disease, please visit the ILD Clinical Trials page of this Web site.